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Abstract
Background: Mortality rates associated with acute kidney injury (AKI) vary among critically ill patients. Outcomes
are often not corrected for severity or duration of AKI. Our objective was to analyse whether a new variable, AKI
burden, would outperform 1) presence of AKI, 2) highest AKI stage, or 3) AKI duration in predicting 90-day mortality.
Methods: Kidney Diseases: Improving Global Outcomes (KDIGO) criteria using creatinine, urine output and renal
replacement therapy were used to diagnose AKI. AKI burden was defined as AKI stage multiplied with the number
of days that each stage was present (maximum five), divided by the maximum possible score yielding a proportion.
The AKI burden as a predictor of 90-day mortality was assessed in two independent cohorts (Finnish Acute Kidney
Injury, FINNAKI and Simple Intensive Care Studies I, SICS-I) by comparing four multivariate logistic regression models
that respectively incorporated either the presence of AKI, the highest AKI stage, the duration of AKI, or the AKI
burden.
Results: In the FINNAKI cohort 1096 of 2809 patients (39%) had AKI and 90-day mortality of the cohort was 23%.
Median AKI burden was 0.17 (IQR 0.07–0.50), 1.0 being the maximum. The model including AKI burden (area under
the receiver operator curve (AUROC) 0.78, 0.76–0.80) outperformed the models using AKI presence (AUROC 0.77,
0.75–0.79, p = 0.026) or AKI severity (AUROC 0.77, 0.75–0.79, p = 0.012), but not AKI duration (AUROC 0.77, 0.75–0.79,
p = 0.06). In the SICS-I, 603 of 1075 patients (56%) had AKI and 90-day mortality was 28%. Median AKI burden was
0.19 (IQR 0.08–0.46). The model using AKI burden performed better (AUROC 0.77, 0.74–0.80) than the models using
AKI presence (AUROC 0.75, 0.71–0.78, p = 0.001), AKI severity (AUROC 0.76, 0.72–0.79. p = 0.008) or AKI duration
(AUROC 0.76, 0.73–0.79, p = 0.009).
Conclusion: AKI burden, which appreciates both severity and duration of AKI, was superior to using only presence
or the highest stage of AKI in predicting 90-day mortality. Using AKI burden or other more granular methods may
be helpful in future epidemiological studies of AKI.
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Background
Acute kidney injury (AKI) is an abrupt decline in renal
function which is defined by the Kidney Disease Improv-
ing Global Outcomes (KDIGO) criteria and based on
changes in plasma creatinine (Cr), urine output, and use
of renal replacement therapy (RRT) [1]. AKI has become
a primary research focus within intensive care medicine
[2] and many studies have focused on incidence, risk fac-
tors, and outcomes of AKI [3–5]. The mortality rates in
patients with AKI range from 20 to 60%, most likely due
to the heterogeneous populations and the variation in
the use of AKI definitions [6].
Studies generally focus on the presence of AKI as a di-
chotomous variable or report the maximum stage, but
often do not incorporate duration of AKI. Yet, both higher
severity and longer duration of AKI are associated with in-
creased hospital and long-term mortality [7–10]. Moreover,
patients fulfilling both Cr and urine output criteria of AKI
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have been found to constantly have higher mortality com-
pared to those with only one of the two criteria [7, 11]. Fur-
thermore, the time-dependant nature of AKI and renal
recovery has been shown to have an important prognostic
impact [12, 13]. However, no study has incorporated the
duration of different stages of AKI and evaluated their asso-
ciation with outcomes.
Theoretically, one would expect a prediction model in-
cluding not only AKI severity but also AKI duration (in here
referred to as “AKI burden”), to better separate patients ac-
cording to their risk of death. For instance, a patient with
transient AKI Stage 1 on day 2 of hospital admission would
be expected to have a lower risk of death compared to a pa-
tient with AKI Stage 1 during the first 5 days of admission
[8]. Classifying AKI patients according to their AKI burden
compared to only AKI stage may partially explain hetero-
geneity in this patient group.
Our objective was to analyse whether a new vari-
able, AKI burden, would predict 90-day mortality bet-
ter than either 1) the presence of AKI, 2) the highest
AKI stage, or 3) the duration of AKI alone, by con-
ducting post-hoc analyses of two independent cohorts:
the Finnish Acute Kidney Injury (FINNAKI) study [3],
and the Simple Intensive Care Studies-I (SICS-I) [14].
We hypothesized that AKI burden would predict 90-
day mortality better than the presence, the duration,
or the severity of AKI only.
Methods
Study design, setting and participants
This study was a post-hoc analysis of the FINNAKI [3]
and SICS-I cohort studies [14].
The FINNAKI was a prospective, observational, multi-
centre cohort study on the incidence, risk factors, and out-
comes of AKI in 17 Finnish ICUs between 1 September
2011 and 1 February 2012. All emergency ICU admissions,
regardless of the expected length of ICU stay, and all
elective patients expected to stay in the ICU for more than
24 h were included. The excluded patients were: 1) pa-
tients under 18 years of age; 2) elective patients whose ex-
pected length of stay was less than 24 h; 3) readmitted
patients who had received RRT during the previous ICU
admission; 4) patients on chronic dialysis; 5) patients with
insufficient language skills or not permanently living in
Finland; 6) intermediate care patients; 7) transferred pa-
tients who had already participated in the study for 5 days;
and 8) organ donors. In the current study, we further ex-
cluded patients from one study site as data of urine output
were collected by different method. The Ethics Committee
of the Department of Surgery in Helsinki University
Central Hospital approved the FINNAKI study protocol
with a deferred, written consent obtained from the patient
or proxy as soon as possible. The Finnish National Insti-
tute of Health approved data collection from medical
records of deceased patients. Statistics Finland provided
data on 90-day survival status.
The SICS-I was a prospective observational single-
centre cohort study on the association between physical
examination and cardiac output conducted between 25
March 2015 and 4 July 2017 and included all acutely ad-
mitted critically ill patients in one ICU in the northern
Netherlands [15]. Exclusion criteria were discharge
within 24 h and/or absence of informed consent. The
local ethical institutional review board approved this
study.
Data source, variables and study size
In both cohorts, daily AKI status was defined according
to the complete KDIGO criteria based on plasma cre-
atinine (Cr), hourly urinary output (all patients had urin-
ary catheters) and the use of RRT separately [16]. Day 1
was defined as the calendar day of admission. The obser-
vation period was the first five calendar days. Baseline
Cr in the FINNAKI database was defined as the most re-
cent value from the previous year excluding the week
preceding admission. If unavailable, baseline Cr was esti-
mated using the Modification of Diet in Renal Disease
(MDRD) equation as recommended [17]. In the SICS-I
cohort an absolute baseline Cr was not available and was
also estimated using the MDRD equation in all patients
except when suffering chronic renal failure. Information
about whether patients suffered from chronic renal fail-
ure with in the SICS-I cohort was available from the
Nationale Intensive Care Evaluatie (NICE) registry,
where a baseline serum creatinine above 177 μmol/L was
defined as chronic renal failure [18]. In the FINNAKI
cohort, the time labels of each UO recording along with
the amount of urine and patient weight were transferred
from the electronic patient data management systems to
an electronic calculator maintained by Tieto Ltd., which
provided the UO in mL/kg/h for all data. The study size
was set by the sizes of the available cohorts. The AKI
burden was considered as the main determinant in this
analysis. The primary outcome was 90-day mortality, for
which data on patients’ vital status were obtained from
municipal record databases for FINNAKI (Finnish popu-
lation register) and SICS-I.
AKI burden
The AKI burden was calculated over a maximum of 5
days. We first assigned a different weight to each level of
AKI (AKI 1 = 1, AKI 2 = 2, AKI 3 = 3), and we scored
each weight twice daily, both for Cr and urine output.
To account for the duration of AKI, we then multiplied
the total weight with the observation time in days. Fi-
nally, we divided this score by the maximum possible
score during the observation period to prevent under-
estimation of AKI burden in patients with missing data
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(the maximum score was 30, if there were no missing
data, for examples see Table 1). The AKI burden at each
specific day was maximal (i.e. 6) if patients received
RRT. Higher proportions reflect higher AKI burden. We
used arbitrarily defined cut-offs to create three categor-
ies of AKI burden (low burden, <0.25; medium burden,
0.25–0.50; high burden, >0.75). To ensure burden scores
were representative, we evaluated mortality rates in dif-
ferent subtypes of AKI.
Missing data
We handled missing data in each cohort following the
original statistical methods. In the FINNAKI cohort no
imputations were performed. In the SICS-I cohort, pre-
dictor variables were imputed using multiple imputa-
tions, but data on Cr, urine output, and mortality were
not imputed [19]. We appreciated missing Cr and urine
output data by only calculating the AKI burden as a pro-
portion of data which were available (i.e., neglecting
missing data) (Table 1). Further, we performed a sensi-
tivity analysis excluding patients who deceased during
the five-day observation period to assess whether this in-
fluenced the models.
Statistical analysis
We present data as means (with standard deviations
(SD)) or medians (with interquartile ranges (IQR)) de-
pending on distributions. Categorical data are presented
in proportions. Outcomes are calculated as odds ratios
(OR) with 95% confidence intervals (CI). Student’s T-
test, Mann-Whitney U test or the Chi-square tests are
used as appropriate.
We used the previously published logistic regression
model from FINNAKI and the logistic regression model of
SICS-I as the main models for predicting 90-day mortality;
these models will from now on be referred to as the ‘original
models’. The original model of FINNAKI included age, pres-
ence of chronic liver failure, malignancy, arteriosclerosis,
diabetes mellitus, systolic heart failure, or chronic immuno-
suppression, pre-morbid functional status (regarding daily
activities), as well as presence of hypotension or resuscita-
tion prior to ICU admission and ICU admission type [20].
The original model of SICS-I included age, vasopressor dose,
respiratory rate, atrial fibrillation, systolic and diastolic blood
pressure, level of consciousness following the alert, verbal,
pain or unresponsive (AVPU) score, central temperature,
and mottling rate scored on the knee (obtained during a
one-time examination within 24 h of admission) [19].
In each cohort, we constructed four models: the ori-
ginal model including presence of AKI as a dichotomous
variable (model A), the original model including the
highest stage of AKI as severity of AKI (model B), the
original model and the duration of AKI (model C) and
the original model and the AKI burden (model D). We
calculated pseudo R2, applied Hosmer-Lemeshow good-
ness of fit test, assessed area under the ROC and used
DeLongs test to compare the area under the ROC of the




Of 2901 FINNAKI study patients, 92 patients were ex-
cluded due to difference in recording urine output at
one study site. In that study site, urine output was col-
lected cumulatively instead of hourly, which made it not
possible to assess the hourly urine output following the
method used for the FINNAKI study. The median obser-
vation period was 4 days (IQR 2–5); 1601 patients (55%)
were discharged, and 167 patients (6%) deceased before
5 days.
FINNAKI - AKI
Of the remaining 2809 patients, 1096 patients (39%) had
AKI at least once during the first 5 days of ICU admis-
sion (Additional file 1: Figure S1). AKI Burden could be
calculated for 2793 patients (99%). The proportions of
missing values for Cr and urine output during the study
period are shown in Additional file 1: Table S1. Among
1096 patients with AKI during ICU stay the median AKI


















Pt. UO - Cr UO - Cr UO - Cr UO - Cr UO - Cr
1 2 3 3 3 . . . . . . 4 12 11 11/12 = 0.92
2 . . 1 1 0 0 0 0 0 0 8 24 2 2/24 = 0.08
3 0 0 0 0 0 0 0 0 0 0 10 30 0 0/30 = 0
4 2 2 3 3 3 3 3 3 3 3 10 30 28 28/30 = 0.93
5 1 1 3 3 3 3 . . . . 6 18 14 14/18 = 0.77
RRT*
Abbreviations: Pt Patient, UO Urine Output, Cr Creatinine, RRT Renal replacement therapy. Maximal score = days multiplied by 3 (highest stage of AKI). *Although
based on UO and Cr, the patient had maximal stage 2, as the patient received RRT, the burden for that day was maximal, so 6
Wiersema et al. BMC Nephrology            (2020) 21:1 Page 3 of 8
burden observed during the first 5 days of admission was
0.17 (IQR 0.07–0.50) (Additional file 1: Figure S2). Of
these, 641 patients (58%) had low burden (< 0.25), 186
patients (17%) had medium burden (0.25–0.50) and 269
patients (25%) had high burden (> 0.50). The highest
stage of AKI was stage 1 in 482 patients (44%), stage 2
in 224 patients (20%), and stage 3 in 390 patients (36%).
RRT was instigated in 260 patients (24%).
FINNAKI - Outcomes
At 90-day follow up, 653 patients (23%) had died.
Table 2 presents baseline characteristics of survivors
and non-survivors. In patients with low, medium and
high AKI burden, mortality rates were 27% (CI 23–31),
35% (CI 29–42) and 44% (CI 38–50), respectively
(Fig. 1). Univariate logistic regression showed that pres-
ence of AKI, the severity of AKI, the duration of AKI,
and AKI burden all were associated with 90-day mortal-
ity (Table 3). There was no significant difference in
mortality between patients who had AKI stage 1 based
on urine output and patients who had AKI stage 1
based on Cr (p = 0.88).
FINNAKI - multivariate models
The Odds Ratio (OR) for 90-day mortality was the highest
for AKI burden 4.56 (95%CI 3.22–6.53). Discrimination
(AUC) of the burden model (AUROC 0.78, 0.76–0.80) was
statistically significantly superior compared to presence of
AKI (AUROC 0.77, 0.75–0.79, p = 0.023), severity of AKI
(AUROC 0.77, 0.75–0.79, p = 0.015), but not statistically
significantly different compared to the duration of AKI
(AUROC 0.77, 0.75–0.79, p = 0.06) (Table 3). The model
with duration of AKI did not have a statistically significant
better performance compared to the presence of AKI (p =
0.08) or the severity of AKI (p = 0.63). The sensitivity ana-
lysis excluding patients deceased within 5 days confirmed
these results.





Age, years (SD) 2156 58.9 (16.8) 653 67.9 (14.0)
Gender, male (%) 2156 1368 (63.5) 653 424 (64.9)
BMI, kg/m2 (SD) 2137 29.1 (27.7) 647 27.9 (16.5)
Baseline creatinine, mmol/L (IQR) 1340 74 (60–90) 450 78 (63–103)
Co-morbidities
Hypertension, n (%) 2143 979 (45.7) 650 350 (53.8)
Diabetes mellitus, n (%) 2156 470 (21.8) 653 137 (21.0)
COPD, n (%) 2142 180 (8.4) 650 73 (11.2)
Systolic heart failure, n (%) 2138 213 (10.0) 647 109 (16.8)
Chronic liver failure, n (%) 2136 60 (2.8) 643 49 (7.6)
Chronic renal failure*, n (%) 2147 118 (5.5) 650 63 (9.7)
Pre-ICU daily medication
Diuretic, n (%) 2125 550 (25.9) 634 229 (36.1)
Statin, n (%) 2127 633 (29.8) 639 195 (30.5)
Metformin, n (%) 2125 270 (12.7) 639 65 (10.2)
NSAID, n (%) 2080 190 (9.1) 618 51 (8.3)
Corticosteroid, n (%) 2132 118 (5.5) 642 96 (15.0)
Admission
Emergency, n (%) 2156 1828 (85.9) 653 623 (95.7)
Operative, n (%) 2156 824 (38.2) 653 164 (25.1)
Mechanical ventilation, n (%) 2156 1404 (65.1) 653 531 (81.3)
Vasopressor use, n (%) 2156 1212 (56.2) 653 461 (70.6)
SAPS II (SD) 2156 35.2 (14.0) 653 54.4 (18.2)
SOFA score (SD) 2156 6.4 (3.1) 653 9.6 (3.9)
*Chronic renal failure defined as eGRF <60ml/min/1.73 m2. Abbreviations: SD Standard Deviation, BMI Body Mass Index, IQR Inter Quartile Range, COPD Chronic
Obstructive Pulmonary Disease, NSAID Non-steroidal anti- inflammatory drugs, SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure
Assessment score
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SICS-I
The SICS-I cohort included 1075 patients. The median
observation period was 3 days (IQR 2–5); 575 patients
(53%) were discharged and 118 patients (11%) deceased
within 5 days. In total, 603 patients (56%) had AKI at
some point during the first 5 days of their admission.
AKI burden could be calculated in 1055 patients (98%)
and median burden of all 603 patients with AKI was
0.19 (IQR 0.08–0.46) (Additional file 1: Figure S3). The
proportions of missing values for Cr and urine output
during the study period are shown in Additional file 1:
Table S2. Of the 1075, 297 patients (28%) had died dur-
ing 90-day follow-up, which was significantly associated
with mortality (Additional file 1: Figure S4). The ob-
served OR was 6.03 (95%CI 3.50–10.38) for AKI burden.
The AUROC of the model including AKI burden (0.77,
95%CI 0.74–0.80) was better compared to the AUROC
of the models including the presence of AKI (0.75,
95%CI 0.71–0.77) (p = 0.001), the severity of AKI (0.76,
95%CI 0.72–0.79) (p = 0.008) or the duration of AKI
(0.76, 95%CI 0.73–0.79) (p = 0.009) (Table 4).
Discussion
Key results
In this post-hoc analysis of two large prospective cohorts
we found that AKI burden was superior for prediction of
90-day mortality in comparison to severity or presence
of AKI. In comparison to duration of AKI, 90-day mor-
tality prediction was improved by AKI burden in the
SICS-I cohort, but remained comparable in the FIN-
NAKI cohort.
Comparison to previous studies
Our results corroborate the findings of a study by
Mandelbaum et al. [8], who investigated the empirical
relationships between oliguria, Cr disturbances, and
mortality. However, that study was a single centre
study and did not use a fixed mortality endpoint. Coca
et al. investigated both duration and severity of post-
operative AKI separately, and showed similar results
to ours in diabetic patients [9]. A study by Truche
et al. aimed to investigate the association of AKI dur-
ation with mortality and found that both the duration
Fig. 1 Burden of acute kidney injury and subsequent mortality rate in the FINNAKI cohort. * Low burden = below 0.25, medium = above 0.25 but
below 0.50, high = above 0.50
Table 3 Multivariate models in FINNAKI





Original model 0.15 8.22 0.41 0.76 0.74–0.78
(A) Presence of AKIb 2.35 (1.96–2.81) 1.94 (1.59–2.37) 0.16 8.54 0.38 0.77 0.75–0.79
(B) Severity of AKIb 1.45 (1.35–1.57) 1.37 (1.25–1.49) 0.16 7.26 0.51 0.77 0.75–0.79
(C) Duration of AKIb 3.46 (2.74–4.37) 2.74 (2.10–3.57) 0.16 5.93 0.65 0.77 0.75–0.79
(D) AKI burdenb 4.97 (3.65–6.77) 4.56 (3.22–6.53) 0.17 10.71 0.22 0.78 0.76–0.80
Abbreviations: AKI Acute Kidney Injury, OR Odds Ratio, CI Confidence Interval, H-L Hosmer Lemeshow, GoF Goodness of Fit, AUROC Area under the receiver
operating curve.aOR of the different methods for AKI in the corresponding model, which were categorical (A and B), or per additional day or point (C and D).
bModel A, B and C included 2732 patients, Model D included 2707 patients
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of AKI and the duration of renal recovery were associ-
ated with 28-day mortality [12]. They argued that
time-dependent variables representing the course of
AKI should be taken in to account for diagnostic and
prognostic purposes, however, no urine output data
were available and thus these conclusions were based
on Cr AKI only [12]. We confirmed these conclusions
in two separate cohorts, where both Cr and urine out-
put were available, and additionally incorporated se-
verity to establish the AKI burden.
Implications
Data of incidence, staging and mortality of AKI
among critically ill patients are increasing [21]. Many
studies focus on prediction models for mortality and
on finding appropriate ways for stratification of AKI
in these models. Modelling AKI appeared difficult
due to different AKI criteria and more importantly,
different types of AKI exist. There is, however, not
yet one superior method for integrating the different
stages of AKI, varying from a stage 1 AKI based on
urine output to a stage 3 AKI based on Cr, and dur-
ation of AKI. AKI burden as a sort of area under
the curve to represent the severity or impact of AKI
in mortality models may be a step toward for includ-
ing AKI in prediction models. AKI burden can be
calculated easily, handles missing data and could po-
tentially incorporate duration along with severity.
We showed, in two independent large cohorts that
AKI burden helps to better appreciate the severity
and duration of different types of AKI. The two co-
horts differed in terms of selection criteria and logic-
ally also in AKI incidences and mortality rates. More
importantly, the original models (FINNAKI admis-
sion model based on previous medical history versus
SICS model based on signs of clinical examination)
were very different. As our hypothesis stands for
both cohorts, AKI burden improved the prognostic
performance of the 90-day mortality model, irre-
spective of the differences in selection criteria and
the admission variables which formed the model.
Limitations
There are some limitations that need to be considered.
First, as our data sets were to some extent incomplete,
we analysed the available data to censor and correct for
missing data as much as possible. Nevertheless, we were
lacking data on Cr and urine output all 5days in both
cohorts, as patients could have been discharged to the
ward (in which case a low burden would be expected) or
deceased during these first 5 days (in which case a
higher burden would be expected). However, we ob-
served no change in the models after excluding the pa-
tients who died during the five-day observation period.
Although missing data are handled to some extent by
AKI burden, those may still have influence: in a case
with few valid values close to 0 and missing data, AKI
burden may be underestimated; while in a case with few
valid values close to 3 and missing data, it may be over-
estimated. Despite these shortcomings AKI burden still
was a statistically stronger predictor than AKI presence
and severity. Second, ideally, the observation period to
estimate AKI burden would be longer, e.g. 7 days [22].
The observation period of 5 days were calendar days,
meaning that the observation time is not entirely equal
throughout all patients, although we corrected for miss-
ing data in the burden calculation. Optimally, the AKI
burden would be a proportion of the same amount of
data for every patient. Unfortunately, this remains a
challenge for observational studies in critical care, as
length of stay varies between patients and urine output
data may be missing while transferred to the ward. Using
multiple imputations could have optimized our analysis.
Third, we used the MDRD formula to estimate baseline
creatinine if not available. This method has inherent lim-
itations as it may underestimate AKI in younger patients
and overestimate AKI in the elderly [23]. Fourth, our ap-
proach was to give equal weight to both urine output
and Cr AKI stages, although some reports have illus-
trated that different stages of urine output and Cr AKI
handled separately do not associate with mortality with
equal strength [7]. However, sensitivity analysis, showed
results to be robust as there was no significant difference
in mortality between AKI stage 1 based on urine output
Table 4 Multivariate models in SICS-I





Original model 0.15 8.22 0.41 0.76 0.74–0.78
(A) Presence of AKIb 2.12 (1.60–2.82) 1.72 (1.24–2.36) 0.14 2.87 0.94 0.75 0.71–0.78
(B) Severity of AKIb 1.44 (1.29–1.61) 1.36 (1.20–1.54) 0.15 6.53 0.58 0.76 0.72–0.79
(C) Duration of AKIb 3.13 (2.26–4.32) 2.68 (1.84–3.92) 0.15 3.62 0.88 0.76 0.73–0.79
(D) AKI burdenb 6.95 (4.36–11.11) 6.03 (3.50–10.38) 0.16 8.18 0.42 0.77 0.74–0.80
Abbreviations: AKI Acute Kidney Injury, OR Odds Ratio, CI Confidence Interval, H-L Hosmer Lemeshow, GoF Goodness of Fit, AUROC Area under the receiver
operating curve. aOR of the different methods for AKI in the corresponding model, which were categorical (A and B), or per additional day or point (C and D). bAll
models included 1032 patients
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or Cr. Finally, we anticipated that AKI burden had re-
sulted in a more clinically significant increase in the pre-
diction ability compared to presence or severity of AKI.
Despite the statistically significant difference, the clinical
significance of this finding may be limited. However, we
believe that this more granular method is helpful in fu-
ture epidemiological research.
Generalizability
We included a heterogeneous population; investigation
of subgroups might show our burden model performs
better or worse in predicting mortality in patient groups
with different AKI etiologies, for instance sepsis or shock
patients. We validated our results in a separate cohort,
which is a major strength of our study and shows that
our results apply to different cohorts. Our observations
encourage researchers to look beyond stage or duration
of AKI and incorporate AKI burden as risk factor.
Conclusions
We found that calculated AKI burden, which included
both severity and duration of AKI, was superior com-
pared to only the presence of AKI, or the severity of AKI
for predicting 90-day mortality in two large, independent
cohorts of critically ill patients. Using AKI burden or
other more granular methods may be helpful in future
epidemiological studies of AKI.
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